magnapen

combination of above 2 cpds; low levels in bones after intramuscular administration in hip replacement; RN given refers to (2S-(2alpha,5alpha,6beta)-isomer)

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Related Diseases

1.	Infections 01/01/1980 - "These results demonstrate the outstanding value of Magnapen in treating a wide variety of infections in general practice." 01/01/1980 - "The treatment of infections in general practice with magnapen: a multicentre trial." 01/01/1979 - "Magnapen treatment of infections in the elderly." 01/01/1980 - "Six hundred and forty-seven infections of the respiratory tract, urinary tract and the skin and soft tissues in 646 patients were treated with oral Magnapen (250 mg ampicillin + 250 mg flucloxacillin) four times each day. "
2.	Wounds and Injuries (Trauma) 08/01/1978 - "Postoperatively the patients patients received 2.0 g Magnapen by intramuscular injection every 6 h for up to 72 h until removal of the wound drains. "
3.	Surgical Wound Infection 08/01/1978 - "6. The plasma, hip capsule, cancellous and ground up bone concentrations of ampicillin after this dose of Magnapen do not, however, exceed the MICs of the Gram negative anaerobes that sometimes cause postoperative wound infections in these patients."

Related Drugs and Biologics

1.	Ampicillin (Omnipen)
2.	Floxacillin (Flucloxacillin)
3.	Capsules (Microcapsules)

Related Therapies and Procedures

1.	Intramuscular Injections